ATHIRA PHARMA INC. -
0,6500
27-ноября-24 11:17:05
15 мин. задержка
Акции
+0,0300
+4,84%
Сегодняшний диапазон
0,6100 - 0,6500
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
02 авг 2022 14:30:00 Источник Nasdaq GlobeNewswire
-
25 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
22 июн 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
07 июн 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
19 май 2022 11:06:13 Источник Nasdaq GlobeNewswire
-
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
16 май 2022 15:49:31 Источник Nasdaq GlobeNewswire
-
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
16 май 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
12 май 2022 15:05:02 Источник Nasdaq GlobeNewswire
-
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
11 май 2022 15:15:00 Источник Nasdaq GlobeNewswire
-
09 май 2022 06:00:02 Источник Nasdaq GlobeNewswire
-
05 май 2022 11:03:56 Источник Nasdaq GlobeNewswire
-
05 май 2022 07:00:03 Источник Nasdaq GlobeNewswire
-
04 май 2022 17:46:09 Источник Nasdaq GlobeNewswire
-
26 апр 2022 07:00:03 Источник Nasdaq GlobeNewswire
-
20 апр 2022 08:02:06 Источник Nasdaq GlobeNewswire
-
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
05 апр 2022 15:04:20 Источник Nasdaq GlobeNewswire
-
04 апр 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
30 мар 2022 11:12:04 Источник Nasdaq GlobeNewswire
-
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
24 мар 2022 15:05:01 Источник Nasdaq GlobeNewswire
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
21 мар 2022 06:05:00 Источник Nasdaq GlobeNewswire